A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis

Statens Serum Institut38 enrolled

Overview

The primary objective is to assess the safety of two doses of C-Tb (0.01 and 0.1 µg/0.1 mL) when administered intradermally by the Mantoux technique to patients in the acute phase of treatment against active TB. The secondary objectives are to assess the immune response of two doses (0.01 and 0.1 µg/0.1 mL) of C-Tb from the size of induration and to assess the safety of unpreserved C-Tb and C-Tb preserved with 0.5% phenol (local reactions).

This clinical trial is a single centre phase Ib open dose adjustment study with respect to the dose of C-Tb combined with a double blind randomised, split-body comparison of unpreserved C-Tb and C-Tb preserved with 0.5% phenol (each patient receives the unpreserved version in one arm and the preserved version in the other arm).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

QUADRUPLE

Enrollment

Conditions

Tuberculosis

Interventions

rdESAT-6 + rCFP-10 (C-Tb)BIOLOGICAL

rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: The patient: 1. Has signed an informed consent 2. Is willing and likely to comply with the trial procedures 3. Has been diagnosed with active TB and has been in treatment ≤ 60 days at the time of inclusion * has 1 documented positive sputum smear microscopy result * has positive culture * has a positive PCR result for tuberculosis * has a compatible clinical picture of TB with the intention to treat 4. Has a positive T-spot assay or a QuantiFERON®-TB Gold In Tube test 5. Is prepared to grant authorized persons access to their medical records Exclusion Criteria: The patient: 1. Has been in treatment with a product which is likely to modify the immune response within 3 months prior to the day of inclusion (e.g., immunoglobulin, systemic corticosteroids, methotrexate, azathioprine, cyclosporine or blood products) 2. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. BCG, MMR, yellow fever, oral typhoid vaccines) 3. Has a known congenital or acquired immune deficiency 4. Has a disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis) 5. Is infected with HIV 6. Has severe scarring, burn, rash, eczema, psoriasis, or any other skin disease at or near the injection sites 7. Has a condition where blood drawings pose more than minimal risk for the patient, such as haemophilia, other coagulation disorders, or significantly impaired venous access 8. Is actively participating in another clinical trial 9. Is pregnant according to urine pregnancy test at inclusion 10. Has a condition which in the opinion of the investigator is not suitable for participation in the study

Locations (1)

St George's University of London

London, London SW17 0RE, United Kingdom

Outcomes

Primary Outcomes

Local and systemic adverse reactions at the injection sites within 28 days after application of the tests (0.01/0.1 µg C-Tb).

Time frame: Within 28 days after the injections

Secondary Outcomes

Immune response of 2 doses (0.01 and 0.1 µg/0.1 mL) of C-Tb from the size of induration; the safety of unpreserved C-Tb and C-Tb preserved with 0.5% phenol and the pain associated with the injection of unpreserved C-Tb and preserved C-Tb

Time frame: Within 28 days after the injections

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.